Tamoxifen

Pharmacologic Category

Antineoplastic Agent, Estrogen Receptor Antagonist; Selective Estrogen Receptor Modulator (SERM)

Dosing: Adult

Note: For the treatment of breast cancer, patients receiving both tamoxifen and chemotherapy should receive treatment sequentially, with tamoxifen following completion of chemotherapy.

Breast cancer, risk reduction (pre- and postmenopausal high-risk females): Oral: 20 mg once daily for 5 years.

Breast cancer, treatment: Oral:

Adjuvant therapy: 20 mg once daily

Duration of therapy: The American Society of Clinical Oncology (ASCO) guidelines for Adjuvant Endocrine Therapy of Hormone-Receptor Positive Breast Cancer (Focused Update) recommend the following durations of therapy based on menopausal status (Burstein 2014):

Pre- or perimenopausal at endocrine therapy initiation: Tamoxifen for an initial duration of 5 years; if pre- or perimenopausal (or status cannot be determined) after 5 years of therapy, may continue tamoxifen for a total duration of 10 years. If postmenopausal after 5 years of tamoxifen therapy, may continue tamoxifen for a total duration of 10 years, or switch to an aromatase inhibitor (AI) for up to a total duration of 10 years of endocrine therapy.

Postmenopausal at endocrine therapy initiation: Tamoxifen for a total duration of 10 years or tamoxifen for an initial duration of 5 years, followed by an AI for up to 5 years (for a total duration of 10 years of endocrine therapy) or tamoxifen for 2 to 3 years, followed by an AI for up to 5 years (for a total duration of 7 to 8 years of endocrine therapy) or an AI for 5 years.

Ductal carcinoma in situ (DCIS) (females), to reduce the risk for invasive breast cancer: 20 mg once daily for 5 years.

Metastatic: 20 mg once daily. Although the manufacturer's labeling recommends dosing of 20 to 40 mg daily (with doses >20 mg administered in 2 divided doses), clinical benefit has not been demonstrated with doses above 20 mg daily (Bratherton 1984).

Guideline recommendations: The American Society of Clinical Oncology (ASCO) guidelines for Endocrine Therapy for Hormone-Receptor Positive Metastatic Breast Cancer recommend the following based on menopausal status (Rugo 2016):

Premenopausal: Tamoxifen (in combination with ovarian suppression) may be offered as first-line therapy in patients with no prior endocrine therapy or in those who have received prior treatment with ovarian suppression and an AI; tamoxifen (with continued ovarian suppression) may also be offered as second-line therapy. Tamoxifen alone may be considered, but combination therapy is preferred.

Postmenopausal: Tamoxifen may be offered as second-line therapy in patients with no prior endocrine therapy. In patients who have received prior endocrine therapy with tamoxifen, tamoxifen may be offered first- or second-line in patients with late relapse (>12 months since adjuvant therapy). In patients who have received prior endocrine therapy with an AI, tamoxifen may be offered as first- or second-line therapy.

Duration of therapy: Continue tamoxifen treatment until documented disease progression (documented by imaging, clinical examination, or disease-related symptoms).

Endometrial carcinoma, recurrent, metastatic, or high-risk (endometrioid histologies only) (off-label use): Oral:

Monotherapy: 20 mg twice daily until disease progression or unacceptable toxicity (Thigpen 2001).

Combination therapy: 20 mg twice daily for 3 weeks (alternating with megestrol acetate every 3 weeks); continue alternating until disease progression or unacceptable toxicity) (Fiorica 2004).

Gynecomastia (off-label use): Oral: 20 mg once daily for up to 12 months (Boccardo 2005; Fradet 2007). The majority of published experiences have been in adult males with prostate cancer receiving bicalutamide. Use has also been reported in patients with idiopathic gynecomastia.

Idiopathic male infertility (off label use): Oral: 20 to 30 mg once daily for 3 to 6 months, then proceed to assisted reproductive therapy if pregnancy has not been achieved (Chua 2013; Colpi 2018).

Induction of ovulation (in breast cancer patients) (off-label use): Oral: 60 mg daily starting on the second or third day of the menstrual cycle (in combination with low-dose follicle-stimulating hormone [FSH]), and continued until the day of hCG administration (Oktay 2005).

Mastalgia, severe (off-label use): Oral: 10 mg once daily for 3 months; may consider further treatment if relapse occurs (Fentiman 1988).

Ovarian cancer, advanced and/or recurrent (off-label use): Oral: 20 mg twice daily (Hatch 1991; Markman 1996).

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Chronic dialysis: No dosage adjustment necessary (Janus 2013).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Pediatric

McCune-Albright syndrome; precocious puberty: Limited data available: Children 2 to 10 years: Oral: 20 mg once daily; dosing based on a trial of 25 girls ≤10 years of age (range: 2.9 to 10.9 years) who received treatment for 1 year; frequency of vaginal bleeding episodes were decreased; growth velocity was significantly decreased prior to pretreatment rates as was skeletal maturation; ovarian and uterine volumes were increased; further studies are needed (Eugester 2003)

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling (not studied).

Chronic dialysis: No dosage adjustment necessary based on experience in adult patients (Janus 2013).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; the effect of hepatic dysfunction on tamoxifen pharmacokinetics has not been determined.

Use: Labeled Indications

Breast cancer, risk reduction: Risk reduction in females at high risk: To reduce the incidence of breast cancer in adult females at high risk for breast cancer

Breast cancer, treatment:

Adjuvant treatment: Adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer; to reduce the incidence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer

Ductal carcinoma in situ: To reduce the risk of invasive breast cancer in adult females with ductal carcinoma in situ (following breast surgery and radiation)

Metastatic breast cancer: Treatment of adult patients with estrogen receptor-positive metastatic breast cancer

Use: Off-Label: Adult

Desmoid tumors, progressive or recurrentLevel of Evidence [C]

Data from a study evaluating the use of tamoxifen (in combination with sulindac) suggest that tamoxifen may be beneficial for the treatment of this condition Ref.

Endometrial carcinoma, recurrent, metastatic, or high-risk (endometrioid histologies only)Level of Evidence [B]

Data from two phase II trials in patients with advanced or recurrent endometrial carcinoma support the use of tamoxifen for the treatment of this condition Ref.

GynecomastiaLevel of Evidence [A]

Data from controlled trials support the use of tamoxifen for preventing or treating antiandrogen-associated gynecomastia in prostate cancer patients Ref. Access Full Off-Label Monograph

Idiopathic male infertilityLevel of Evidence [C, G]

In meta-analyses of randomized controlled trials evaluating the treatment of idiopathic male infertility, tamoxifen may improve semen parameters in some patients; an increase in pregnancy rates was not observed in all studies Ref.

Based on the European Academy of Andrology guideline, management of oligo-astheno-teratozoospermia, a recommendation cannot be made for or against the use of tamoxifen in the treatment of idiopathic male infertility based on the currently available evidence Ref.

Induction of ovulation (in breast cancer patients)Level of Evidence [B]

Data from a prospective controlled study in women with breast cancer support the use of tamoxifen (in combination with low-dose follicle-stimulating hormone [FSH]) for ovarian stimulation, although letrozole in combination with FSH may be preferred due to lower peak estradiol levels with this combination Ref.

Mastalgia, severeLevel of Evidence [B]

Data from a small controlled trial suggest that tamoxifen may be beneficial for the treatment of severe mastalgia Ref. Evidence from a meta-analysis of controlled trials showed that tamoxifen was associated with an improvement in breast pain in women with cyclical mastalgia Ref. Access Full Off-Label Monograph

Ovarian cancer, advanced and/or recurrentLevel of Evidence [C]

Data from two studies evaluating the use of tamoxifen for the treatment of advanced ovarian cancer suggest that tamoxifen may be beneficial for the treatment of this condition Ref.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Oncology:

“American Society of Clinical Oncology Clinical Practice Guideline: Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer: Focused Update,” November 2018

“American Society of Clinical Oncology Clinical Practice Guideline: Endocrine Therapy for Hormone-Receptor Positive Metastatic Breast Cancer,” May 2016

“American Society of Clinical Oncology Clinical Practice Guideline Update: Use of Endocrine Therapy for Breast Cancer Risk Reduction,” September 2019

“American Society of Clinical Oncology Clinical Practice Guideline Update: Breast Cancer Follow-Up and Management After Primary Treatment,” March 2012

National Comprehensive Cancer Network® (NCCN), "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)," Breast Cancer

National Comprehensive Cancer Network® (NCCN), "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)," Breast Cancer Risk Reduction

National Comprehensive Cancer Network® (NCCN), "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)," Ovarian Cancer

National Comprehensive Cancer Network® (NCCN), "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)," Soft Tissue Sarcoma

National Comprehensive Cancer Network® (NCCN), "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)," Uterine Neoplasms

Stroke:

AHA/ASA, “Guidelines for the Prevention of Stroke in Women,” 2014

Administration: Oral

Administer tablets or oral solution with or without food. Use supplied dosing cup for oral solution.

Administration: Pediatric

Oral: Administer tablets or oral solution with or without food; use supplied dosing cup for oral solution.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).

Storage/Stability

Oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze or refrigerate. Protect from light. Discard opened bottle after 3 months.

Tablets: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Avoid excessive heat.

Extemporaneously Prepared

A 0.5 mg/mL oral suspension may be prepared with tablets. Place two 10 mg tablets into 40 mL purified water and let stand ~2 to 5 minutes. Stir until tablets are completely disintegrated (dispersion time for each 10 mg tablet is ~2 to 5 minutes). Administer immediately after preparation. To ensure the full dose is administered, rinse glass several times with water and administer residue.

Lam MS, "Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs," Pharmacotherapy, 2011, 31(2):164-92.[PubMed 21275495]

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat breast cancer.

• It is used to lower the chance of breast cancer in women with a higher chance of getting it. It may lower the chance of getting cancer in the other breast after one has cancer.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Hot flashes

• Nausea

• Vomiting

• Weight loss

• Constipation

• Diarrhea

• Trouble sleeping

• Anxiety

• Weight gain

• Back pain

• Bone pain

• Dizziness

• Muscle pain

• Joint pain

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Infection

• High calcium like weakness, confusion, fatigue, headache, nausea and vomiting, constipation, or bone pain.

• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain.

• Severe cerebrovascular disease like change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes.

• Bruising

• Bleeding

• Severe loss of strength and energy

• Swelling of arms or legs

• Burning or numbness feeling

• Pelvic pain or pressure

• Menstrual changes

• No menstrual periods

• Abnormal vaginal bleeding

• Vaginal discharge

• Vision changes

• Lump in breast

• Breast soreness or pain

• Decreased sex drive

• Sexual dysfunction

• Depression

• Skin changes

• Severe headache

• Painful urination

• Blood clots like numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; chest pain; shortness of breath; fast heartbeat; or coughing up blood.

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin.

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication when used in females for breast cancer prevention or treatment of ductal carcinoma in situ:

Soltamox:https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lblMG.pdf

Contraindications

Known hypersensitivity (eg, angioedema, serious skin reactions) to tamoxifen or any component of the formulation; concurrent warfarin therapy or history of deep vein thrombosis or pulmonary embolism (when tamoxifen is used for breast cancer risk reduction in women at high risk for breast cancer or risk reduction of invasive breast cancer after treatment of ductal carcinoma in situ [DCIS])

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Thrombocytopenia (usually grade 1 or 2) and/or leukopenia may occur; neutropenia and pancytopenia have been reported rarely. Although the relationship to tamoxifen therapy is uncertain, rare hemorrhagic episodes have occurred in patients with significant thrombocytopenia. Monitor blood counts periodically.

• Gynecologic effects/malignancies: [US Boxed Warning]: Serious and life-threatening events from the use of tamoxifen include uterine malignancies (including fatal cases). The incidence rates are per 1,000 woman-years and were estimated from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial in females at high risk for breast cancer. For endometrial adenocarcinoma, the incidence was 2.20 for tamoxifen versus 0.71 for placebo; for uterine sarcoma, the incidence was 0.17 for tamoxifen versus 0.04 for placebo. Assess potential benefits of tamoxifen versus potential risks of serious events in females at high risk for breast cancer and in ductal carcinoma in situ (DCIS) when considering tamoxifen to reduce the risk of developing breast cancer. For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks. Most uterine malignancies seen with tamoxifen are classified as endometrial adenocarcinoma, although uterine sarcomas have also been reported. Uterine sarcoma associated with tamoxifen use was generally associated with a higher FIGO stage (III/IV) at diagnosis, poor prognosis, and short survival. Uterine sarcomas are more frequently associated with a tamoxifen duration of ≥2 years. Endometrial hyperplasia, polyps, endometriosis, uterine fibroids, and ovarian cysts have occurred. Amenorrhea and menstrual irregularities have been reported with tamoxifen use. Monitor and promptly evaluate any report of abnormal vaginal bleeding, menstrual irregularities, changes in vaginal discharge, or pelvic pain/pressure. Patients receiving or who have received tamoxifen in the past should have annual gynecological examinations.

• Hepatotoxicity: Hepatocellular carcinoma has been reported in patients receiving adjuvant tamoxifen at doses of 40 mg twice daily (twice the recommended dose). Tamoxifen has also been associated with elevated transaminases, as well as other less common (and occasionally fatal) hepatic abnormalities including fatty liver, cholestasis, hepatitis, and hepatic necrosis. Monitor liver function periodically.

• Ocular effects: Visual disturbances, including retinal vein thrombosis, retinopathy, corneal changes, color perception changes and increased incidence of cataracts (and the need for cataract surgery) have been reported. Promptly evaluate any visual disturbance.

• Thromboembolic events: [US Boxed Warning]: Serious and life-threatening events from tamoxifen include stroke and pulmonary embolism (PE), including fatal cases. The incidence rates are per 1,000 woman-years and were estimated from the NSABP P-1 trial in women at high risk for breast cancer. For stroke, the incidence was 1.43 for tamoxifen versus 1.00 for placebo; for PE, the incidence was 0.75 for tamoxifen versus 0.25 for placebo. Assess potential benefits of tamoxifen versus potential risks of serious events in females at high risk for breast cancer and in females with DCIS when considering tamoxifen to reduce the risk of developing breast cancer. For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks. PE events occurred at an average of 27 months from tamoxifen initiation (range: 2 to 60 months), Deep vein thrombosis events occurred at an average of 19 months (range: 2 months to 57 months) into therapy, and stroke occurred at an average of 30 months (range: 1 to 63 months) after tamoxifen initiation. Tamoxifen is contraindicated in women with DCIS and for the reduction in breast cancer incidence in women at high risk who require warfarin or have a history of deep vein thrombosis or pulmonary embolism. An increased incidence of thromboembolic events has been associated with use; risk is increased with concomitant chemotherapy. Use with caution in individuals with a history of thromboembolic events. Advise patients to immediately report signs/symptoms of thromboembolism.

Disease-related concerns:

• Bone mineral density: Tamoxifen use may be associated with changes in bone mineral density (BMD) and the effects may be dependent upon menstrual status. In postmenopausal women, tamoxifen use is associated with a protective effect on BMD, preventing loss of BMD which lasts over the 5-year treatment period. In premenopausal women, a decline (from baseline) in BMD mineral density has been observed in women who continued to menstruate; may be associated with an increased risk of fractures.

• Hyperlipidemia: Hypercholesterolemia and postmarketing cases of hyperlipidemias have been reported. Periodic monitoring of cholesterol and triglycerides may be indicated in patients with preexisting hyperlipidemias.

• Metastatic breast cancer: Local disease flare and increased bone and tumor pain may occur; may be associated with (good) tumor response; onset is shortly after therapy initiation and usually resolves rapidly. In some patients with bone metastasis, hypercalcemia has occurred, usually within a few weeks of therapy initiation. Institute appropriate hypercalcemia management; discontinue tamoxifen if hypercalcemia is severe.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

• Selective serotonin reuptake inhibitors (SSRI): Concomitant use with select SSRIs may result in decreased tamoxifen efficacy. Strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine) are reported to interfere with transformation to the active metabolite endoxifen; when possible, select alternative medications with minimal or no impact on endoxifen levels (Sideras 2010). Weak CYP2D6 inhibitors (eg, venlafaxine, citalopram) have minimal effect on the conversion to endoxifen (Jin 2005); escitalopram is also a weak CYP2D6 inhibitor. In a retrospective analysis of breast cancer patients taking tamoxifen and SSRIs, concomitant use of paroxetine and tamoxifen was associated with an increased risk of death due to breast cancer (Kelly 2010).

Special populations:

• CYP2D6 poor metabolizers: Lower plasma concentrations of endoxifen (active metabolite) have been observed in patients with reduced CYP2D6 activity (Jin 2005; Schroth 2009) and may be associated with reduced efficacy, although data is conflicting. Routine CYP2D6 testing is not recommended at this time in order to determine optimal endocrine therapy (Visvanathan 2009).

Dosage form specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).

Geriatric Considerations

Studies have shown tamoxifen to be effective in the treatment of primary breast cancer in elderly women. Comparative studies with other antineoplastic agents in elderly women with breast cancer had more favorable survival rates with tamoxifen. Initiation of hormone therapy rather than chemotherapy is justified for elderly patients with metastatic breast cancer who are responsive.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).

Reproductive Considerations

Tamoxifen may induce ovulation (Steiner 2005) or cause menstrual cycle irregularities. Based on animal data, tamoxifen may impair embryo implantation in females of reproductive potential, but may not reliably cause infertility, even if menstrual cycles are irregular.

Confirm a negative pregnancy test in females of reproductive potential prior to initiating tamoxifen therapy. Females of reproductive potential should use effective nonhormonal contraception during tamoxifen therapy and for 2 months following the last tamoxifen dose.

Pregnancy Considerations

Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to tamoxifen may cause fetal harm. However, available data are insufficient to establish a causal relationship; no pattern of birth defects has been observed, and the long term effects of tamoxifen on development are not known (Braems 2011; Schuurman 2019). There have been reports of vaginal bleeding, birth defects, spontaneous abortions and fetal death following use in pregnancy. Tamoxifen use during pregnancy may have a potential long-term risk to the fetus of a diethylstilbestrol (DES)-like syndrome (based on animal data).

Breast-Feeding Considerations

It is not known if tamoxifen is present in breast milk.

Tamoxifen has been shown to inhibit early postpartum milk production; effects on established milk production is not known. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 3 months following the last tamoxifen dose.

Briggs' Drugs in Pregnancy & Lactation

• Tamoxifen

Adverse Reactions

>10%:

Cardiovascular: Vasodilation (41%), flushing (33%), hypertension (11%), peripheral edema (11%)

Dermatologic: Skin changes (6% to 19%), skin rash (13%)

Endocrine & metabolic: Hot flash (3% to 80%), fluid retention (32%), weight loss (23%), amenorrhea (16%)

Gastrointestinal: Nausea (5% to 26%), nausea and vomiting (12%)

Genitourinary: Vaginal discharge (12% to 55%), irregular menses (13% to 25%), vaginal hemorrhage (2% to 23%)

Hematologic & oncologic: Lymphedema (11%)

Nervous system: Fatigue (≤18%), mood changes (12% to 18%), pain (3% to 16%), depression (2% to 12%)

Neuromuscular & skeletal: Asthenia (≤18%), arthritis (14%), arthralgia (11%)

Respiratory: Pharyngitis (14%)

1% to 10%:

Cardiovascular: Chest pain (5%), venous thrombosis (5%), edema (4%), ischemic heart disease (3%), deep vein thrombosis (≤2%)

Dermatologic: Diaphoresis (6%), alopecia (≤5%)

Endocrine & metabolic: Infrequent uterine bleeding (9%), weight gain (9%), menstrual disease (6%), hypercholesterolemia (3%), ovarian cyst (3%)

Gastrointestinal: Abdominal pain (9%), constipation (4% to 8%), diarrhea (7%), dyspepsia (6%), abdominal cramps (1%), anorexia (1%)

Genitourinary: Urinary tract infection (10%), leukorrhea (9%), mastalgia (6%), vaginitis (5%), vulvovaginitis (5%)

Hematologic & oncologic: Thrombocytopenia (2% to 10%), anemia (5%), breast neoplasm (5%), neoplasm (5%; second primary)

Hepatic: Increased serum aspartate aminotransferase (5%), increased serum bilirubin (2%)

Hypersensitivity: Hypersensitivity reaction (3%)

Infection: Infection (≤9%), sepsis (≤6%)

Nervous system: Insomnia (9%), dizziness (8%), headache (8%), anxiety (6%), paresthesia (5%)

Neuromuscular & skeletal: Back pain (10%), bone fracture (7%), osteoporosis (7%), ostealgia (6%), arthropathy (5%), myalgia (5%), musculoskeletal pain (3%)

Ophthalmic: Cataract (7%)

Renal: Increased serum creatinine (2%)

Respiratory: Cough (4% to 9%), dyspnea (8%), flu-like symptoms (6%), bronchitis (5%), sinusitis (5%), throat irritation (oral solution: 5%)

Miscellaneous: Cyst (5%)

Frequency not defined:

Cardiovascular: Cerebrovascular accident

Dermatologic: Pruritus vulvae

Endocrine & metabolic: Hypercalcemia

Gastrointestinal: Cholestasis, dysgeusia

Genitourinary: Vaginal dryness

Hematologic & oncologic: Tumor flare (during treatment of metastatic breast cancer; generally resolves with continuation; includes increased lesion size and erythema)

Hepatic: Hepatic necrosis, hepatitis, liver steatosis

Nervous system: Tumor pain (during treatment of metastatic breast cancer; generally resolves with continuation)

<1%: Hepatic neoplasm, superficial thrombophlebitis

Postmarketing: Angioedema, bullous pemphigoid, corneal changes, cutaneous lupus erythematosus (Andrew 2014), endometrial carcinoma, endometrial hyperplasia, endometrial polyps, endometriosis, erythema multiforme, hypertriglyceridemia, impotence, interstitial pneumonitis, leukopenia, loss of libido (males), malignant neoplasm of uterus, neutropenia, pancreatitis, pancytopenia, pulmonary embolism, retinal thrombosis, retinopathy, Stevens-Johnson syndrome, subacute cutaneous lupus erythematosus (Andrew 2014), uterine carcinoma, uterine fibroids, vision color changes, visual disturbance

Allergy and Idiosyncratic Reactions

• Selective Estrogen Receptor Modulator (SERM) Allergy

Metabolism/Transport Effects

Substrate of CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C9 (weak)

Drug Interactions Open Interactions

Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity. Risk D: Consider therapy modification

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Risk C: Monitor therapy

Anastrozole: Tamoxifen may decrease the serum concentration of Anastrozole. Risk X: Avoid combination

Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Asunaprevir is contraindicated in combination with drugs metabolized by CYP2D6 for which increased levels are associated with ventricular arrhythmias and sudden death (eg, thioridazine, flecanide, propafenone); use caution with any CYP2D6 substrate. Risk D: Consider therapy modification

Bexarotene (Systemic): May decrease the serum concentration of Tamoxifen. Risk C: Monitor therapy

Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Chloroquine: Tamoxifen may enhance the adverse/toxic effect of Chloroquine. Specifically, concomitant use of tamoxifen and chloroquine may increase the risk of retinal toxicity. Risk C: Monitor therapy

CloBAZam: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible. Risk D: Consider therapy modification

CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Risk X: Avoid combination

CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. Management: Consider alternatives to concomitant use of strong CYP3A4 inducers and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination. Some combinations are specifically contraindicated by manufacturers; others may have recommended dose adjustments. If combined, monitor for increased substrate effects. Risk D: Consider therapy modification

Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Risk D: Consider therapy modification

Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Risk D: Consider therapy modification

Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Risk D: Consider therapy modification

Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring. Risk D: Consider therapy modification

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Hydroxychloroquine: Tamoxifen may enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity. Risk C: Monitor therapy

Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Letrozole: Tamoxifen may decrease the serum concentration of Letrozole. Risk C: Monitor therapy

Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment. Risk D: Consider therapy modification

MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Risk D: Consider therapy modification

Mipomersen: Tamoxifen may enhance the hepatotoxic effect of Mipomersen. Risk C: Monitor therapy

Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. Risk D: Consider therapy modification

Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators. Risk X: Avoid combination

Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Ribociclib: May increase the serum concentration of Tamoxifen. Management: Concurrent use of ribociclib with tamoxifen is not indicated. Use of this combination may increase the effects and toxicities of tamoxifen. Risk D: Consider therapy modification

Rifamycin Derivatives: May increase the metabolism of Tamoxifen. Management: Consider alternatives to coadministration of rifampin and tamoxifen. If this combination cannot be avoided, monitor for decrease tamoxifen efficacy. It is unclear if rifapentine or rifabutin would participate in this interaction. Risk D: Consider therapy modification

Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents. Risk C: Monitor therapy

Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Risk D: Consider therapy modification

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Tamoxifen may increase the serum concentration of Vitamin K Antagonists. Risk X: Avoid combination

Food Interactions

Grapefruit juice may decrease the metabolism of tamoxifen. Management: Monitor for increased effects/toxicity with concomitant use.

Test Interactions

T4 elevations (which may be explained by increases in thyroid-binding globulin) have been reported; not accompanied by clinical hyperthyroidism.

Variations in the vagina smear karyopyknotic index and various degrees of Pap smear estrogen effect have been observed in postmenopausal women taking tamoxifen.

Gene Testing May Be Considered

• CYP2D6 - Tamoxifen

Monitoring Parameters

CBC with platelets, serum calcium, liver function tests; triglycerides and cholesterol (in patients with preexisting hyperlipidemias); INR and PT (in patients on vitamin K antagonists); pregnancy test (prior to treatment in females of reproductive potential); monitor for abnormal vaginal bleeding, menstrual irregularities, pelvic pain/pressure; breast and gynecologic exams (baseline and routine), mammogram (baseline and routine); signs/symptoms of DVT (leg swelling, tenderness) or PE (shortness of breath); ophthalmic exam (if vision problem or cataracts); bone mineral density (premenopausal women). Monitor adherence.

Advanced Practitioners Physical Assessment/Monitoring

Obtain CBC with platelets, serum calcium, liver function tests, triglycerides and cholesterol (in patients with preexisting hyperlipidemias), and INR and PT (in patients on vitamin K antagonists). Ensure patient obtains breast exams, mammogram, and gynecologic exams at baseline and routine. Order ophthalmic exam (if vision problem or cataracts) and bone mineral density (premenopausal women). Assess for abnormal vaginal bleeding and signs/symptoms of DVT or PE.

Nursing Physical Assessment/Monitoring

Check ordered labs and tests and report abnormalities. Monitor and educate patient to report any signs of DVT (leg swelling, tenderness) or PE (shortness of breath). Teach patients about the importance of periodic ophthalmic evaluations and annual gynecological exams and mammograms with long-term use. Educate patients about avoiding grapefruit juice.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral:

Soltamox: 10 mg/5 mL (150 mL) [sugar free; contains alcohol, usp, propylene glycol; licorice-aniseed flavor]

Tablet, Oral:

Generic: 10 mg, 20 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Nolvadex D: 20 mg

Generic: 10 mg, 20 mg

Anatomic Therapeutic Chemical (ATC) Classification

• L02BA01

Generic Available (US)

May be product dependent

Pricing: US

Solution (Soltamox Oral)

10 mg/5 mL (per mL): $5.54

Tablets (Tamoxifen Citrate Oral)

10 mg (per each): $0.47 - $1.89

20 mg (per each): $3.79

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G0 and G1 phases; therefore, tamoxifen is cytostatic rather than cytocidal.

Pharmacodynamics/Kinetics

Absorption: Well absorbed

Distribution: Widely distributed to most tissues, particularly tissues that inhibit estrogen receptors (Perry 2012)

Protein binding: Highly protein bound (Perry 2012)

Metabolism: Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen

Bioavailability: Tamoxifen oral solution is bioequivalent to tamoxifen tablets

Half-life elimination: Tamoxifen: ~5 to 7 days; N-desmethyl tamoxifen: ~14 days

Time to peak, serum:

Children 2 to 10 years (female): ~8 hours

Adults: ~5 hours

Excretion: ~65% (primarily fecal); <30% as unchanged drug and unconjugated metabolites

Clearance: Higher (~2.3-fold) in female pediatric patients (2 to 10 years) compared to adult breast cancer patients; within pediatric population, clearance faster in children 2 to 6 years compared to older children

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

Although significant myelosuppression with associated altered hemostasis has been reported for many chemotherapeutic agents, myelosuppression is not common with tamoxifen and no specific precautions appear to necessary.

Related Information

• Drugs With Actionable Pharmacogenomic Recommendations
• Oral Medications That Should Not Be Crushed or Altered
• Safe Handling of Hazardous Drugs

Index Terms

ICI-46474; Nolvadex; Tamoxifen Citras; Tamoxifen Citrate

FDA Approval Date

December 30, 1977

References

Adamopoulos DA, Nicopoulou S, Kapolla N, Vassilopoulos P, Karamertzanis M, Kontogeorgos L. Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. Fertil Steril. 1995;64(4):818-824.[PubMed 7672156]

Adamopoulos DA, Nicopoulou S, Kapolla N, Karamertzanis M, Andreou E. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril. 1997;67(4):756-762.[PubMed 9093207]

Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril. 2003;80(4):914-920.[PubMed 14556812]

AinMelk Y, Belisle S, Carmel M, Jean-Pierre T. Tamoxifen citrate therapy in male infertility. Fertil Steril. 1987;48(1):113-117.[PubMed 3297810]

Andrew P, Valiani S, MacIsaac J, Mithoowani H, Verma S. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. Breast Cancer Res Treat. 2014;148(1):1-5.[PubMed 25292419]10.1007/s10549-014-3150-0

Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23(4):808-815.[PubMed 15681525]

Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547-1551. doi: 10.1634/theoncologist.2011-0121.[PubMed 22020212]

Bratherton DG, Brown CH, Bucha a R, et al, “A Comparison of Two Doses of Tamoxifen (Nolvadex) in Postmenopausal Women With Advanced Breast Cancer: 10 mg bd Versus 20 mg bd,” Br J Cancer, 1984, 50(2):199-205.[PubMed 6380554]

Breznik R, Borko E. Effectiveness of antiestrogens in infertile men. Arch Androl. 1993;31(1):43-48.[PubMed 8373285]

Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269. doi: 10.1200/JCO.2013.54.2258.[PubMed 24868023]

Buvat J, Buvat-Herbaut M, Marcolin G, Ardaens-Boulier K. Antiestrogens as treatment of female and male infertilities. Horm Res. 1987;28(2-4):219-229.[PubMed 9093207]

Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476-1484. doi: 10.1016/j.fertnstert.2013.03.029.[PubMed 23635348]

Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013;1(5):749-757. doi: 10.1111/j.2047-2927.2013.00107.x.[PubMed 23970453]

Colpi GM, Francavilla S, Haidl G, et al. European Academy of Andrology guideline management of oligo-astheno-teratozoospermia. Andrology. 2018;6(4):513-524. doi: 10.1111/andr.12502.[PubMed 30134082]

Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. doi: 10.1016/S0140-6736(12)61963-1.[PubMed 23219286]

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” Lancet, 2005, 365(9472):1687-717.[PubMed 15894097]

Eastell R, Adams JE, Coleman RE, et al, “Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,” J Clin Oncol, 2008, 26(7):1051-7.[PubMed 18309940]

Eugster EA, Rubin SD, Reiter EO, et al, “Tamoxifen Treatment for Precocious Puberty in McCune-Albright Syndrome: A Multicenter Trial,” J Pediatr, 2003, 143(1):60-6.[PubMed 12915825]

Fentiman IS, Caleffi M, Hamed H, et al. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Sur. 1988;75(9):845-846.[PubMed 3052691]

Fiorica JV, Brunetto VL, Hanjani P, et al, “Phase II trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study,” Gynecol Oncol, 2004, 92(1):10-4[PubMed 14751131]

Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007;52(1):106-114.[PubMed 17270340]

Goetz MP, Kamal A, and Ames MM, “Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response,” Clin Pharmacol Ther, 2008, 83(1):160-6.[PubMed 17882159]

Hansmann A, Adolph C, Vogel T, et al, “High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors,” Cancer, 2004, 100(3):612-20.[PubMed 14745880]

Hatch KD, Beecham JB, Blessing JA, et al, “Responsiveness of Patients With Advanced Ovarian Carcinoma to Tamoxifen. A Gynecologic Oncology Group Study of Second-Line Therapy in 10 Patients,” Cancer, 1991, 68(2):269-71.[PubMed 2070324]

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics committee on drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Janus N, Launay-Vacher V, Thyss A, et al, “Management of Anticancer Treatment in Patients Under Chronic Dialysis: Results of the Multicentric CANDY (CANcer and DialYsis) Study,” Ann Oncol, 2013, 24(2):501-7.[PubMed 23038759]

Jin Y, Desta Z, Stearns V, et al, “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” J Natl Cancer Inst, 2005, 97(1):30-9.[PubMed 15632378]

Kelly CM, Juurlink DN, Gomes T, et al, “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study,” BMJ, 2010, 340:c693.[PubMed 20142325]

Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen—a randomized controlled study. Int J Androl. 1992;15(1):14-18.[PubMed 1544695]

Markman M, Iseminger KA, Hatch KD, et al, “Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report,” Gynecol Oncol, 1996, 62(1):4-6.[PubMed 8690289]

Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347-4353. doi: 10.1200/JCO.2005.05.037.[PubMed 15824416]

Omar MI, Pal RP, Kelly BD, et al. Benefits of empiric nutritional and medical therapy for semen parameters and pregnancy and live birth rates in couples with idiopathic infertility: a systematic review and meta-analysis. Eur Urol. 2019;75(4):615-625. doi: 10.1016/j.eururo.2018.12.022.[PubMed 30630643]

Perdoná S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005;6(5):295-300.[PubMed 1586337]

Perry MC, ed. Chemotherapeutic agents: tamoxifen. In: The Chemotherapy Source Book. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.

Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069-3103. doi: 10.1200/JCO.2016.67.1487.[PubMed 27217461]

Schroth W, Goetz MP, Hamann U, et al, “Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen,” JAMA, 2009, 302(13):1429-36.[PubMed 19809024]

Schuurman TN, Witteveen PO, van der Wall E, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019. doi: 10.1007/s10549-019-05154-7. [Epub ahead of print].[PubMed 30707336]

Serretta V, Altieri V, Morgia G, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer. 2012;10(3):174-179.[PubMed 22502790]

Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]

Sideras K, Ingle JN, Ames MM, et al, “Coprescription of Tamoxifen and Medications That Inhibit CYP2D6,” J Clin Oncol, 2010, 28(16):2768-76.[PubMed 20439629]

Soltamox (tamoxifen citrate) [prescribing information]. Raleigh, NC: Fortovia Therapeutics Inc; June 2019.

Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of mastalgia: a meta-analysis of randomised trials. Breast. 2007;16(5):503-512.[PubMed 17509880]

Steiner AZ, Terplan M, and Paulson RJ, “Comparison of Tamoxifen and Clomifene Citrate for Ovulation Induction: A Meta-Analysis,” Hum Reprod, 2005, 20(6):1511-5.[PubMed 15845599]

Tamoxifen citrate [prescribing information]. Greenville, NC: Mayne Pharma; July 2016.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,” Fertil Steril, 2008, 89(3):505-22.[PubMed 18243179]

Thigpen T, Brady MF, Homesley HD, et al, “Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” J Clin Oncol, 2001, 19(2):364-7.[PubMed 11208827]

Török L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia. 1985;17(5):497-501.[PubMed 4061890]

US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.

Vehmanen L, Elomaa I, Blomqvist C, et al, “Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status,” J Clin Oncol, 2006, 24(4):675-80.[PubMed 16446340]

Visvanathan K, Chlebowski RT, Hurley P, et al, “American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction,” J Clin Oncol, 2009, 27(19):3235-58.[PubMed 19470930]

Willis KJ, London DR, Bevis MA, Butt WR, Lynch SS, Holder G. Hormonal effects of tamoxifen in oligospermic men. J Endocrinol. 1977;73(1):171-178.[PubMed 323393]

Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219.[PubMed 17555487]

Brand Names: International

Bilem (TH); Citofen (HR); Crisafeno (PY); Cytotam (LK); Cytotam-10 (ET); Diemon (AR); Fenahex (PH); Genox (AU, NZ); Ginarsan (PE); Ginarsan Forte (PE); Gynatam (PH); Gyraxen (PH); Kessar (CL, FR, GR, IT, ZA); Mamofen (IN, LK); Medtax (PH); Moxafen (AE, BH, CY, IQ, IR, JO, KR, KW, LY, OM, SA, SY, YE); Neophedan (ZA); Neophedan-10 (ZW); Nolvadex (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CL, CR, CY, DE, DO, EG, ES, ET, FI, FR, GH, GM, GN, GR, GT, GY, HK, HN, HR, IE, IN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, NZ, OM, PA, PK, PL, PR, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZM, ZW); Nolvadex D (LB, LK, MT); Nolvadex-D (AU, CO, CU, EE, HK, NZ, PH, PY, SG, TH, UY); Novofen (EC, SG, TH, TW); Novofen Forte (BZ, GY, SR); Novofen-D (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT); Oncotamox (EC); Retaxim (HR); Soltamox (GB, IE); Tadex (FI, TW); Tamec (CH); Tamifen (AE, BH, CY, IQ, IR, JO, KW, LY, OM, SA, SY, YE); Tamifine (VN); Tamizam (BE, LU); Tamodex (EG); Tamofen (CN, DK, FI, HK, TW); Tamofon (AE, JO); Tamona (BD); Tamophar (AE, BH, KW, QA, SA); Tamoplex (BE, KR, PE, PH); Tamorex (KR); Tamosin (AU); Tamox (IE); Tamoxen (BD, HK, PH); Tamoxifen-Eurogenerics (LU); Tamoxifen-Hexal (LU); Tamoxifen-ratioparm (LU); Tamoxifen-Teva (HU); Tamoxifen-Zeneca (LU); Tamoxin (EG); Tamoxis (LK); Tamoxit (LB); Taxus (EC, PE); Tecnofen (MX); Temolex (BD); Xifen (PH); Zitazonium (CZ, HU, PH, RU)

Last Updated 5/2/20